We use privacy-friendly, cookieless analytics (Plausible) plus one first-party cookie for anonymous visit counting — no advertising and no cross-site tracking. See our Cookie Policy and Privacy Policy.
Federal IDR · Code overview
Out of network Tissue exam under the microscope, level III, CPT 88304
The denial, the code, and the path to recovery.
Out of network Tissue exam under the microscope, level III (CPT 88304) is routinely paid below the billed charge or denied outright. Most practices treat what arrives as the amount owed. Under the No Surprises Act it is an opening offer, and federal independent dispute resolution exists to contest it. We prepare the submission, and we can file it for you.
- Code
- CPT 88304
- Body region
- surgical specimen
- Typical setting
- hospital or reference lab
Microscopic examination of a lower-complexity surgical tissue specimen.
Why Tissue exam under the microscope, level III gets paid short out of network
Anchored to the qualifying payment amount (QPA)
The plan pays Tissue exam under the microscope, level III at its own qualifying payment amount — its median in-network rate for the area — and treats that as the answer. Under the No Surprises Act the QPA is the plan's opening anchor, not a cap, and certified IDR entities weigh several other factors against it.
Out-of-network reduction with no contract on file
With no negotiated rate for Tissue exam under the microscope, level III (CPT 88304), the allowed amount is reduced to an out-of-network schedule that rarely reflects what the surgical specimen procedure actually involves in a hospital or reference lab setting.
Down-coding or documentation holds
Tissue exam under the microscope, level III claims are frequently held or down-coded pending operative notes, then paid short once submitted — a gap federal IDR is designed to contest with the right clinical record attached.
The federal pathway to recovery
There is a defined federal pathway between a payer's underpayment and a binding arbitrated amount: an open negotiation window, an eligibility determination, a batching decision, then arbitration. Each step has a hard deadline, and missing one forfeits the claim. Sydra screens eligibility, assembles the evidence and offer, files, and tracks every deadline so a Tissue exam under the microscope, level III claim never lapses by default.
Providers win roughly 88% of IDR determinations they contest. Sydra is a flat, predictable fee — less than half of what most contingency firms charge. We file it, you keep the recovery.
Tissue exam under the microscope, level III (CPT 88304) — common questions
Can out-of-network Tissue exam under the microscope, level III (CPT 88304) claims go through federal IDR?
Yes. If the item or service qualifies under the No Surprises Act and open negotiation has passed without resolution, either party can initiate independent dispute resolution to contest the payment on CPT 88304.
Why is Tissue exam under the microscope, level III underpaid out of network?
Lower-complexity surgical pathology read out of network by hospital-based pathologists. Insurers anchor to the qualifying payment amount and apply out-of-network reductions, which is exactly what federal IDR exists to contest.
What does Sydra do with a Tissue exam under the microscope, level III denial?
Sydra checks whether the Tissue exam under the microscope, level III claim qualifies, assembles a compliant IDR submission with the supporting evidence and your offer, tracks every deadline, and can file it for you — for a flat fee, never a percentage of the recovery.
Browse all Pathology codes, or return to the Federal IDR hub.
Tissue exam under the microscope, level III denials by state
No outcome is guaranteed. Results vary by claim, payer, specialty, and documentation. Any general figures reflect the published federal record across all disputes, not a prediction about your claim. This is general information, not legal or financial advice.
Medically & clinically reviewed by Dr. John M. Abrahams, MD
Board-certified neurosurgeon and founder of Sydra · Last reviewed September 2026 · About the author
Sources
Figures reflect the published federal record across all disputes, not a prediction about any individual claim. This is general information, not legal or financial advice.